News

Zealand Pharma and OTR Therapeutics have entered into a multi-program strategic collaboration and licensing partnership aimed at discovering and developing a new generation of…
Read More...

Formation Bio and Lynk Pharmaceuticals have announced that Formation Bio has acquired worldwide rights—excluding Greater China—to LNK01006, a next-generation, central nervous system…
Read More...

China’s National Medical Products Administration (NMPA) has approved JASCAYD® (nerandomilast), marking the first new treatment for adults with progressive pulmonary fibrosis (PPF) in…
Read More...

Nanexa AB has entered into a new license and option agreement with Moderna Inc., marking a significant expansion of its long-acting injectable drug-delivery partnerships. The deal…
Read More...

China’s National Medical Products Administration (NMPA) has approved two innovative Sanofi therapies—Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired…
Read More...

Pfizer has released compelling new data from its Phase 3 HER2CLIMB-05 clinical trial, showing that the company’s tyrosine kinase inhibitor, TUKYSA® (tucatinib), significantly improved…
Read More...

Zydus Lifesciences has announced a major strategic partnership with Germany-based Formycon AG to develop and commercialize FYB206, a biosimilar version of the blockbuster immunotherapy…
Read More...

Ajax Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AJ1-11095, the company’s next-generation JAK inhibitor being…
Read More...

Eli Lilly and Company has announced plans to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama, aimed at producing next-generation synthetic medicine active…
Read More...

Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its epinephrine injection USP, 1 mg/mL, in both single-dose (1 mL) and multi-dose (30 mL)…
Read More...

Pfizer has entered into a global collaboration and licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, to advance the development of YP05002, an…
Read More...

Roche announced that the European Commission has granted approval for Gazyva®/Gazyvaro® (obinutuzumab) combined with mycophenolate mofetil (MMF) to treat adults with active Class III or…
Read More...

Inductive Bio, an AI-driven drug discovery company known for developing virtual chemistry laboratories, has been awarded up to $21 million to lead a groundbreaking project aimed at…
Read More...

Viatris Inc. has entered into definitive agreements with Biocon Limited for the sale of its full equity stake in Biocon Biologics Limited, marking a major strategic move as the company…
Read More...

Ionis Pharmaceuticals has received a significant boost in its neurology pipeline with the U.S. Food and Drug Administration granting Breakthrough Therapy designation to zilganersen, the…
Read More...

Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib) for adults with relapsed or refractory…
Read More...

Taiwan-based Formosa Pharmaceuticals (6838.TW) has entered into an exclusive licensing agreement with Singapore-headquartered Rxilient Medical Pte. Ltd., granting the company…
Read More...

Global biopharmaceutical contract development and manufacturing organization (CDMO) AGC Biologics has announced a major expansion of its Cell Line Development Center of Excellence…
Read More...

The U.S. Food and Drug Administration (FDA) has appointed Tracy Beth Høeg, M.D., Ph.D., as the acting director of the Center for Drug Evaluation and Research (CDER), marking a…
Read More...

The U.S. Food and Drug Administration (FDA) has issued new draft guidance identifying specific drug product types for which six-month non-human primate (NHP) toxicity studies can be…
Read More...